{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:06:58Z","timestamp":1792897618597,"version":"4.5.0"},"reference-count":133,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000313","name":"British Society for Antimicrobial Chemotherapy","doi-asserted-by":"publisher","award":["BSAC-2018-0064"],"award-info":[{"award-number":["BSAC-2018-0064"]}],"id":[{"id":"10.13039\/501100000313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773574"],"award-info":[{"award-number":["81773574"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["2017KM79NN"],"award-info":[{"award-number":["2017KM79NN"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG18855"],"award-info":[{"award-number":["IG18855"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007479","name":"Fondazione Cassa di Risparmio di Padova e Rovigo","doi-asserted-by":"publisher","award":["55777 2020.0162"],"award-info":[{"award-number":["55777 2020.0162"]}],"id":[{"id":"10.13039\/100007479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013317","name":"Shanxi Provincial Key Research and Development Project","doi-asserted-by":"publisher","award":["2019JZZY021011"],"award-info":[{"award-number":["2019JZZY021011"]}],"id":[{"id":"10.13039\/501100013317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009108","name":"Shandong University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015335","name":"Modern Agricultural Technology Industry System of Shandong province","doi-asserted-by":"publisher","award":["SDAIT-11-01"],"award-info":[{"award-number":["SDAIT-11-01"]}],"id":[{"id":"10.13039\/501100015335","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015335","name":"Modern Agricultural Technology Industry System of Shandong province","doi-asserted-by":"publisher","award":["SDAIT-21-06"],"award-info":[{"award-number":["SDAIT-21-06"]}],"id":[{"id":"10.13039\/501100015335","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.apsb.2021.11.018","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T18:09:38Z","timestamp":1637345378000},"page":"1805-1824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Contemporary medicinal chemistry strategies for the discovery and optimization of influenza inhibitors targeting vRNP constituent proteins"],"prefix":"10.1016","volume":"12","author":[{"given":"Lingxin","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasulu","family":"Cherukupalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruifang","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8900-861X","authenticated-orcid":false,"given":"Arianna","family":"Loregian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4898-7882","authenticated-orcid":false,"given":"Xinyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2021.11.018_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/irv.12533","article-title":"Advances in measuring influenza burden of disease","volume":"12","author":"Lee","year":"2018","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.apsb.2021.11.018_bib2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3389\/fmed.2019.00109","article-title":"Drugs for influenza treatment: is there significant news?","volume":"6","author":"Principi","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.apsb.2021.11.018_bib3","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/13543784.2019.1606210","article-title":"Investigational antiviral therapies for the\u00a0treatment of influenza","volume":"28","author":"Yang","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.apsb.2021.11.018_bib4","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(05)67338-2","article-title":"Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern","volume":"366","author":"Bright","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2021.11.018_bib5","doi-asserted-by":"crossref","first-page":"104780","DOI":"10.1016\/j.antiviral.2020.104780","article-title":"Put a cork in it: plugging the M2 viral ion channel to sink influenza","volume":"178","author":"Jalily","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.apsb.2021.11.018_bib6","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jama.295.8.joc60020","article-title":"Adamantane resistance among influenza A viruses isolated early during the 2005\u20122006 influenza season in the United States","volume":"295","author":"Bright","year":"2006","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.apsb.2021.11.018_bib7","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1128\/AAC.00650-09","article-title":"Large-scale sequence analysis of M gene of influenza A viruses from different species: mechanisms for emergence and spread of amantadine resistance","volume":"53","author":"Furuse","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2021.11.018_bib8","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/bip.22623","article-title":"Recent progress in designing inhibitors that target the drug-resistant M2 proton channels from the influenza A viruses","volume":"104","author":"Wang","year":"2015","journal-title":"Biopolymers"},{"key":"10.1016\/j.apsb.2021.11.018_bib9","article-title":"Adamantane-resistant influenza a viruses in the world (1902\u20122013): frequency and\u00a0distribution of M2 gene mutations","volume":"10","author":"Dong","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2021.11.018_bib10","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.coph.2016.08.003","article-title":"Antiviral therapies on the horizon for influenza","volume":"30","author":"Naesens","year":"2016","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.apsb.2021.11.018_bib11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.antiviral.2018.07.001","article-title":"Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016\u20122017","volume":"157","author":"Lackenby","year":"2018","journal-title":"Antiviral Res"},{"key":"10.1016\/j.apsb.2021.11.018_bib12","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/QCO.0000000000000498","article-title":"Neuraminidase inhibitor resistance in influenza: a clinical perspective","volume":"31","author":"Lee","year":"2018","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.apsb.2021.11.018_bib13","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1007\/s00018-014-1615-2","article-title":"Antiviral strategies against influenza virus: towards new therapeutic approaches","volume":"71","author":"Loregian","year":"2014","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.apsb.2021.11.018_bib14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/17460441.2019.1560261","article-title":"Novel antiviral drug discovery strategies to tackle drug-resistant mutants of influenza virus strains","volume":"14","author":"Shin","year":"2019","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.apsb.2021.11.018_bib15","doi-asserted-by":"crossref","first-page":"D49","DOI":"10.1016\/j.vaccine.2008.07.039","article-title":"The biology of influenza viruses","volume":"26","author":"Bouvier","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.apsb.2021.11.018_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005062","article-title":"A novel antiviral target structure involved in the RNA binding, dimerization, and nuclear export functions of the influenza A virus nucleoprotein","volume":"11","author":"Kakisaka","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.apsb.2021.11.018_bib17","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nrmicro.2016.87","article-title":"Influenza virus RNA polymerase: insights into the mechanisms of viral RNA synthesis","volume":"14","author":"Te-Velthuis","year":"2016","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.apsb.2021.11.018_bib18","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1073\/pnas.1519772113","article-title":"Identification and characterization of influenza variants resistant to a viral endonuclease inhibitor","volume":"113","author":"Song","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2021.11.018_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002830","article-title":"Structural and biochemical basis for development of influenza virus inhibitors targeting the PA endonuclease","volume":"8","author":"DuBois","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.apsb.2021.11.018_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005923","article-title":"Melioidosis in lower provincial Cambodia: a case series from a prospective study of sepsis in Takeo Province","volume":"11","author":"Schully","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.apsb.2021.11.018_bib21","doi-asserted-by":"crossref","first-page":"a038398","DOI":"10.1101\/cshperspect.a038398","article-title":"Structure and function of the influenza virus transcription and replication machinery","volume":"10","author":"Fodor","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.apsb.2021.11.018_bib22","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nature07720","article-title":"Crystal structure of an avian influenza polymerase PA(N) reveals an endonuclease active site","volume":"458","author":"Yuan","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2021.11.018_bib23","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nature07745","article-title":"The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit","volume":"458","author":"Dias","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2021.11.018_bib24","doi-asserted-by":"crossref","first-page":"9096","DOI":"10.1128\/JVI.00995-10","article-title":"Mutational and metal binding analysis of the endonuclease domain of\u00a0the influenza virus polymerase PA subunit","volume":"84","author":"Cr\u00e9pin","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.apsb.2021.11.018_bib25","doi-asserted-by":"crossref","first-page":"6668","DOI":"10.1021\/jm5007275","article-title":"Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.11.018_bib26","doi-asserted-by":"crossref","first-page":"8915","DOI":"10.1021\/jm401369y","article-title":"New 7-methylguanine derivatives targeting the influenza polymerase PB2 cap-binding domain","volume":"56","author":"Pautus","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.11.018_bib27","first-page":"3353","article-title":"An in\u00a0vitro fluorescence based study of initiation of RNA synthesis by influenza B polymerase","volume":"45","author":"Reich","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.apsb.2021.11.018_bib28","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nature14009","article-title":"Structural insight into cap-snatching and RNA synthesis by influenza polymerase","volume":"516","author":"Reich","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2021.11.018_bib29","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1348-0421.2002.tb02682.x","article-title":"Fine mapping of the subunit binding sites of influenza virus RNA polymerase","volume":"46","author":"Ohtsu","year":"2002","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.apsb.2021.11.018_bib30","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/emboj.2009.138","article-title":"Structural insight into the essential PB1-PB2 subunit contact of the influenza virus RNA polymerase","volume":"28","author":"Sugiyama","year":"2009","journal-title":"Embo J"},{"key":"10.1016\/j.apsb.2021.11.018_bib31","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/nature07120","article-title":"Crystal structure of the polymerase PA(C)\u2012PB1(N) complex from an avian influenza H5N1 virus","volume":"454","author":"He","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2021.11.018_bib32","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/nature07225","article-title":"The structural basis for an essential subunit interaction in influenza virus RNA polymerase","volume":"454","author":"Obayashi","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2021.11.018_bib33","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1021\/acsinfecdis.0c00552","article-title":"Inhibition of influenza virus polymerase by interfering with its protein\u2012protein interactions","volume":"7","author":"Massari","year":"2021","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.apsb.2021.11.018_bib34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.antiviral.2015.11.005","article-title":"Identification of a small-molecule inhibitor of influenza virus via disrupting the subunits interaction of the viral polymerase","volume":"125","author":"Yuan","year":"2016","journal-title":"Antiviral Res"},{"key":"10.1016\/j.apsb.2021.11.018_bib35","doi-asserted-by":"crossref","first-page":"7699","DOI":"10.1021\/acs.jmedchem.5b01474","article-title":"Polymerase acidic protein-basic protein 1 (PA\u2012PB1) protein\u2012protein interaction as a target for next-generation anti-influenza therapeutics","volume":"59","author":"Massari","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.11.018_bib36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1021\/mp900131p","article-title":"Molecular basis of the interaction for an essential subunit PA\u2012PB1 in influenza virus RNA polymerase: insights from molecular dynamics simulation and free energy calculation","volume":"7","author":"Liu","year":"2010","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2021.11.018_bib37","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nsmb.1779","article-title":"Structures of influenza A proteins and insights into antiviral drug targets","volume":"17","author":"Das","year":"2010","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.apsb.2021.11.018_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/38e16278-983f-4cc0-a3b6-b16d078a5d70","article-title":"Importin \u03b13\/Qip1 is involved in multiplication of mutant influenza virus with alanine mutation at amino acid 9 independently of nuclear transport function","volume":"8","author":"Sasaki","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2021.11.018_bib39","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.2174\/1568026617666170224122508","article-title":"Influenza A virus nucleoprotein: a highly conserved multi-functional viral protein as a hot antiviral drug target","volume":"17","author":"Hu","year":"2017","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.apsb.2021.11.018_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002831","article-title":"Structural analysis of specific metal chelating inhibitor binding to the endonuclease domain of influenza pH1N1 (2009) polymerase","volume":"8","author":"Kowalinski","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.apsb.2021.11.018_bib41","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1021\/cb200439z","article-title":"Identification of influenza endonuclease inhibitors using a novel fluorescence polarization assay","volume":"7","author":"Baughman","year":"2012","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.apsb.2021.11.018_bib42","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1128\/AAC.38.12.2827","article-title":"Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds","volume":"38","author":"Tomassini","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2021.11.018_bib43","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1128\/AAC.40.5.1304","article-title":"Anti-influenza virus activities of 4-substituted 2,4-dioxobutanoic acid inhibitors","volume":"40","author":"Hastings","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2021.11.018_bib44","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.antiviral.2007.12.010","article-title":"PA subunit of RNA polymerase as a promising target for anti-influenza virus agents","volume":"78","author":"Nakazawa","year":"2008","journal-title":"Antiviral Res"},{"key":"10.1016\/j.apsb.2021.11.018_bib45","doi-asserted-by":"crossref","first-page":"5504","DOI":"10.1021\/jo015665d","article-title":"Synthesis of natural flutimide and analogous fully substituted pyrazine-2,6-diones, endonuclease inhibitors of influenza virus","volume":"66","author":"Singh","year":"2001","journal-title":"J Org Chem"},{"key":"10.1016\/j.apsb.2021.11.018_bib46","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1021\/jm020334u","article-title":"Use of a pharmacophore model to discover a new class of influenza endonuclease inhibitors","volume":"46","author":"Parkes","year":"2003","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.11.018_bib47","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1128\/AAC.40.5.1189","article-title":"A novel antiviral agent which inhibits the endonuclease of influenza viruses","volume":"40","author":"Tomassini","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2021.11.018_bib48","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1021\/cb400400j","article-title":"Crystallographic fragment screening and structure-based optimization yields a new class of influenza endonuclease inhibitors","volume":"8","author":"Bauman","year":"2013","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.apsb.2021.11.018_bib49","doi-asserted-by":"crossref","first-page":"8086","DOI":"10.1021\/jm500958x","article-title":"Phenyl substituted 4-hydroxypyridazin-3(2H)-ones and 5-hydroxypyrimidin-4(3H)-ones: inhibitors of influenza A endonuclease","volume":"57","author":"Sagong","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.11.018_bib50","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/cmdc.201900084","article-title":"Aryl and arylalkyl substituted 3-hydroxypyridin-2(1H)-ones: synthesis and evaluation as inhibitors of influenza A endonuclease","volume":"14","author":"Sagong","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.apsb.2021.11.018_bib51","doi-asserted-by":"crossref","first-page":"6435","DOI":"10.1016\/j.bmc.2013.08.053","article-title":"Phenyl substituted 3-hydroxypyridin-2(1H)-ones: inhibitors of influenza A endonuclease","volume":"21","author":"Parhi","year":"2013","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.apsb.2021.11.018_bib52","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1021\/ml4001112","article-title":"3-hydroxyquinolin-2(1H)-ones as inhibitors of influenza A endonuclease","volume":"4","author":"Sagong","year":"2013","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.apsb.2021.11.018_bib53","doi-asserted-by":"crossref","first-page":"Rrn1052","DOI":"10.1371\/currents.RRN1052","article-title":"Green tea catechins inhibit the endonuclease activity of influenza A virus RNA polymerase","volume":"1","author":"Kuzuhara","year":"2009","journal-title":"PLoS Curr"},{"key":"10.1016\/j.apsb.2021.11.018_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019825","article-title":"Anti-influenza activity of marchantins, macrocyclic bisbibenzyls contained in liverworts","volume":"6","author":"Iwai","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2021.11.018_bib55","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1016\/j.bmc.2015.07.046","article-title":"Structural and computational study on inhibitory compounds for endonuclease activity of influenza virus polymerase","volume":"23","author":"Fudo","year":"2015","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.apsb.2021.11.018_bib56","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1016\/j.bmc.2010.05.035","article-title":"Anti-influenza activity of phenethylphenylphthalimide analogs derived from thalidomide","volume":"18","author":"Iwai","year":"2010","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.apsb.2021.11.018_bib57","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1016\/j.bmc.2018.07.046","article-title":"Identification of influenza PA-Nter endonuclease inhibitors using pharmacophore- and docking-based virtual screening","volume":"26","author":"Ferro","year":"2018","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.apsb.2021.11.018_bib58","doi-asserted-by":"crossref","first-page":"112048","DOI":"10.1016\/j.ejmech.2020.112048","article-title":"Synthesis and SARs of dopamine derivatives as potential inhibitors of influenza\u00a0virus PA(N) endonuclease","volume":"189","author":"Liao","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2021.11.018_bib59","doi-asserted-by":"crossref","first-page":"104545","DOI":"10.1016\/j.antiviral.2019.104545","article-title":"Antivirals targeting the polymerase complex of influenza viruses","volume":"169","author":"Mifsud","year":"2019","journal-title":"Antiviral Res"},{"key":"10.1016\/j.apsb.2021.11.018_bib60","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40265-018-0899-1","article-title":"Baloxavir: first global approval","volume":"78","author":"Heo","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2021.11.018_bib61","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.antiviral.2018.10.008","article-title":"In\u00a0vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit","volume":"160","author":"Noshi","year":"2018","journal-title":"Antiviral Res"},{"key":"10.1016\/j.apsb.2021.11.018_bib62","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02460-16","article-title":"The PA endonuclease inhibitor RO-7 protects mice from lethal challenge with influenza A or B viruses","volume":"61","author":"Jones","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2021.11.018_bib63","doi-asserted-by":"crossref","first-page":"5504","DOI":"10.1128\/AAC.00888-16","article-title":"A novel endonuclease inhibitor exhibits broad-spectrum anti-influenza virus activity in\u00a0vitro","volume":"60","author":"Jones","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2021.11.018_bib64","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.1038\/s41598-018-27890-4","article-title":"Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil","volume":"8","author":"Omoto","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2021.11.018_bib65","first-page":"346","article-title":"Treatment-emergent influenza variant viruses with reduced baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza","volume":"221","author":"Uehara","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.apsb.2021.11.018_bib66","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2021.11.018_bib67","doi-asserted-by":"crossref","first-page":"9403","DOI":"10.1021\/acs.jmedchem.0c00565","article-title":"Non-rigid diarylmethyl analogs of baloxavir as cap-dependent endonuclease inhibitors of influenza viruses","volume":"63","author":"Ivashchenko","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.11.018_bib68","doi-asserted-by":"crossref","first-page":"10208","DOI":"10.1021\/bi101011j","article-title":"Regulation of influenza RNA polymerase activity and the switch between replication and transcription by the concentrations of the vRNA 5' end, the cap source, and the polymerase","volume":"49","author":"Olson","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.apsb.2021.11.018_bib69","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1021\/acs.jnatprod.8b00656","article-title":"Spirostaphylotrichin X from a marine-derived fungus as an anti-influenza agent targeting RNA polymerase PB2","volume":"81","author":"Wang","year":"2018","journal-title":"J Nat Prod"},{"key":"10.1016\/j.apsb.2021.11.018_bib70","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1093\/nar\/gkx1210","article-title":"Capped RNA primer binding to influenza polymerase and implications for the mechanism of cap-binding inhibitors","volume":"46","author":"Pflug","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.apsb.2021.11.018_bib71","doi-asserted-by":"crossref","first-page":"126639","DOI":"10.1016\/j.bmcl.2019.126639","article-title":"Novel influenza polymerase PB2 inhibitors for the treatment of influenza A infection","volume":"29","author":"Zhang","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2021.11.018_bib72","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1128\/AAC.04623-14","article-title":"Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit","volume":"59","author":"Byrn","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2021.11.018_bib73","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/med.21401","article-title":"The influenza virus polymerase complex: an update on its structure, functions, and significance for antiviral drug design","volume":"36","author":"Stevaert","year":"2016","journal-title":"Med Res Rev"},{"key":"10.1016\/j.apsb.2021.11.018_bib74","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.drudis.2018.01.028","article-title":"Influenza A virus polymerase: an attractive target for next-generation anti-influenza therapeutics","volume":"23","author":"Zhou","year":"2018","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2021.11.018_bib75","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.2174\/0929867325666180706112940","article-title":"Focusing on the influenza virus polymerase complex: recent progress in drug discovery and assay development","volume":"26","author":"Zhang","year":"2019","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.apsb.2021.11.018_bib76","series-title":"Janssen to stop clinical development of pimodivir for influenza","year":"2020"},{"key":"10.1016\/j.apsb.2021.11.018_bib77","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.3390\/molecules25225291","article-title":"Identification of novel influenza polymerase PB2 inhibitors using a cascade docking virtual screening approach","volume":"25","author":"Zhao","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2021.11.018_bib78","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1089\/adt.2015.668","article-title":"An RNA hybridization assay for screening influenza A virus polymerase inhibitors using the entire ribonucleoprotein complex","volume":"13","author":"Roch","year":"2015","journal-title":"Assay Drug Dev Technol"},{"key":"10.1016\/j.apsb.2021.11.018_bib79","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/j.bmcl.2015.03.013","article-title":"Isosteric replacements of the carboxylic acid of drug candidate VX-787: effect of charge on antiviral potency and kinase activity of azaindole-based influenza PB2 inhibitors","volume":"25","author":"Boyd","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2021.11.018_bib80","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1021\/acschembio.9b00552","article-title":"Discovery of influenza polymerase PA\u2012PB1 interaction inhibitors using an in\u00a0vitro split-luciferase complementation-based assay","volume":"15","author":"Zhang","year":"2020","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.apsb.2021.11.018_bib81","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ymeth.2011.08.007","article-title":"Identification of influenza virus inhibitors which disrupt of viral polymerase protein\u2012protein interactions","volume":"55","author":"Chase","year":"2011","journal-title":"Methods"},{"key":"10.1016\/j.apsb.2021.11.018_bib82","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.tips.2009.03.002","article-title":"Emerging antiviral targets for influenza A virus","volume":"30","author":"Krug","year":"2009","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.apsb.2021.11.018_bib83","doi-asserted-by":"crossref","first-page":"5575","DOI":"10.1016\/j.bmcl.2013.08.048","article-title":"Discovery and synthesis of novel benzofurazan derivatives as inhibitors of influenza A virus","volume":"23","author":"Kessler","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2021.11.018_bib84","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/cmdc.201300378","article-title":"The fight against the influenza A virus H1N1: synthesis, molecular modeling, and biological evaluation of benzofurazan derivatives as viral RNA polymerase inhibitors","volume":"9","author":"Pagano","year":"2014","journal-title":"ChemMedChem"},{"key":"10.1016\/j.apsb.2021.11.018_bib85","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1073\/pnas.1119817109","article-title":"Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase","volume":"109","author":"Muratore","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2021.11.018_bib86","doi-asserted-by":"crossref","first-page":"10118","DOI":"10.1021\/jm401560v","article-title":"Structural investigation of cycloheptathiophene-3-carboxamide derivatives targeting influenza virus polymerase assembly","volume":"56","author":"Massari","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.11.018_bib87","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bbagen.2011.11.003","article-title":"Structure-based discovery of anti-influenza virus A compounds among medicines","volume":"1820","author":"Fukuoka","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.apsb.2021.11.018_bib88","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejmech.2017.06.015","article-title":"Exploring the cycloheptathiophene-3-carboxamide scaffold to disrupt the interactions of the influenza polymerase subunits and obtain potent anti-influenza activity","volume":"138","author":"Desantis","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2021.11.018_bib89","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.antiviral.2019.03.003","article-title":"Potent and broad-spectrum cycloheptathiophene-3-carboxamide compounds that target the PA\u2012PB1 interaction of influenza virus RNA polymerase and possess a high barrier to drug resistance","volume":"165","author":"Nannetti","year":"2019","journal-title":"Antiviral Res"},{"key":"10.1016\/j.apsb.2021.11.018_bib90","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1021\/acs.jmedchem.5b00012","article-title":"A broad anti-influenza hybrid small molecule that potently disrupts the interaction of polymerase acidic protein-basic protein 1 (PA\u2012PB1) subunits","volume":"58","author":"Massari","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.11.018_bib91","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1021\/acs.jmedchem.5b01935","article-title":"4,6-diphenylpyridines as promising novel anti-influenza agents targeting the PA\u2012PB1 protein\u2012protein interaction: structure\u2012activity relationships exploration with the aid of molecular modeling","volume":"59","author":"Trist","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.11.018_bib92","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ejmech.2018.08.032","article-title":"Synthesis and biological evaluation of a library of hybrid derivatives as inhibitors of influenza virus PA\u2013PB1 interaction","volume":"157","author":"D\u2019Agostino","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2021.11.018_bib93","doi-asserted-by":"crossref","first-page":"112944","DOI":"10.1016\/j.ejmech.2020.112944","article-title":"Synthesis and characterization of 1,2,4-triazolo[1,5-a]pyrimidine-2-carboxamide-based compounds targeting the PA\u2012PB1 interface of influenza A virus polymerase","volume":"209","author":"Massari","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2021.11.018_bib94","doi-asserted-by":"crossref","first-page":"113494","DOI":"10.1016\/j.ejmech.2021.113494","article-title":"1,2,4-Triazolo[1,5-a]pyrimidines: Efficient one-step synthesis and functionalization as influenza polymerase PA-PB1 interaction disruptors","volume":"221","author":"Pismataro","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2021.11.018_bib95","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/nbt.1638","article-title":"Identification of influenza A nucleoprotein as an antiviral target","volume":"28","author":"Kao","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2021.11.018_bib96","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1128\/AAC.01219-12","article-title":"Human cytomegalovirus inhibitor AL18 also possesses activity against influenza A and B viruses","volume":"56","author":"Muratore","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2021.11.018_bib97","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1038\/s41598-018-22875-9","article-title":"Exploring ugi-azide four-component reaction products for broad-spectrum influenza antivirals with a high genetic barrier to drug resistance","volume":"8","author":"Zhang","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2021.11.018_bib98","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.antiviral.2016.11.005","article-title":"Identification of a novel small-molecule compound targeting the influenza A virus polymerase PB1\u2012PB2 interface","volume":"137","author":"Yuan","year":"2017","journal-title":"Antiviral Res"},{"key":"10.1016\/j.apsb.2021.11.018_bib99","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.apsb.2021.11.018_bib100","doi-asserted-by":"crossref","first-page":"107512","DOI":"10.1016\/j.pharmthera.2020.107512","article-title":"Favipiravir, an anti-influenza drug against life-threatening RNA virus infections","volume":"209","author":"Shiraki","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.apsb.2021.11.018_bib101","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.1128\/AAC.01156-16","article-title":"Distinct effects of T-705 (favipiravir) and ribavirin on influenza virus replication and viral RNA synthesis","volume":"60","author":"Vanderlinden","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2021.11.018_bib102","doi-asserted-by":"crossref","first-page":"19151","DOI":"10.1073\/pnas.1013592107","article-title":"High-throughput identification of compounds targeting influenza RNA-dependent RNA polymerase activity","volume":"107","author":"Su","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2021.11.018_bib103","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002668","article-title":"A novel small molecule inhibitor of influenza A viruses that targets polymerase function and indirectly induces interferon","volume":"8","author":"Ortigoza","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.apsb.2021.11.018_bib104","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature14008","article-title":"Structure of influenza A polymerase bound to the viral RNA promoter","volume":"516","author":"Pflug","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2021.11.018_bib105","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3851\/IMP2235","article-title":"Influenza nucleoprotein: promising target for antiviral chemotherapy","volume":"23","author":"Cianci","year":"2012","journal-title":"Antivir Chem Chemother"},{"key":"10.1016\/j.apsb.2021.11.018_bib106","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1128\/AAC.02335-12","article-title":"Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus","volume":"57","author":"Lejal","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2021.11.018_bib107","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.bbrc.2010.03.058","article-title":"Discovery of novel antiviral agents directed against the influenza A virus nucleoprotein using photo-cross-linked chemical arrays","volume":"394","author":"Hagiwara","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.apsb.2021.11.018_bib108","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1021\/acsinfecdis.7b00120","article-title":"Broad spectrum inhibitor of influenza A and B viruses targeting the viral nucleoprotein","volume":"4","author":"White","year":"2018","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.apsb.2021.11.018_bib109","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.antiviral.2016.07.024","article-title":"Antiviral activity of KR-23502 targeting nuclear export of influenza B virus ribonucleoproteins","volume":"134","author":"Jang","year":"2016","journal-title":"Antiviral Res"},{"key":"10.1016\/j.apsb.2021.11.018_bib110","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1111\/jcmm.13467","article-title":"Identification of a novel compound targeting the nuclear export of influenza A virus nucleoprotein","volume":"22","author":"Huang","year":"2018","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.apsb.2021.11.018_bib111","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1021\/acs.jmedchem.8b01683","article-title":"Design, synthesis, and biological evaluation of itaconic acid derivatives as potential anti-influenza agents","volume":"62","author":"Sethy","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.11.018_bib112","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.1021\/jm101330h","article-title":"Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3)","volume":"54","author":"Li","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.11.018_bib113","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2021.11.018_bib114","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/bib\/bbr011","article-title":"Old friends in new guise: repositioning of known drugs with structural bioinformatics","volume":"12","author":"Haupt","year":"2011","journal-title":"Brief Bioinform"},{"key":"10.1016\/j.apsb.2021.11.018_bib115","doi-asserted-by":"crossref","first-page":"9375","DOI":"10.1021\/acs.jmedchem.9b00359","article-title":"Overview of recent strategic advances in medicinal chemistry","volume":"62","author":"Wu","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.11.018_bib116","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.drudis.2015.07.012","article-title":"Development of HIV-1 integrase inhibitors: recent molecular modeling perspectives","volume":"20","author":"Su","year":"2015","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2021.11.018_bib117","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.celrep.2019.04.053","article-title":"Naproxen exhibits broad anti-influenza virus activity in mice by impeding viral nucleoprotein nuclear export","volume":"27","author":"Zheng","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2021.11.018_bib118","doi-asserted-by":"crossref","first-page":"7202","DOI":"10.1021\/acs.jmedchem.8b00557","article-title":"From naproxen repurposing to naproxen analogues and their antiviral activity against influenza A virus","volume":"61","author":"Dilly","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.11.018_bib119","doi-asserted-by":"crossref","first-page":"6444","DOI":"10.1021\/acs.jmedchem.6b00628","article-title":"Fragment-based identification of\u00a0influenza endonuclease inhibitors","volume":"59","author":"Credille","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.11.018_bib120","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1039\/C4MB00147H","article-title":"\u201cOld dogs with new tricks\u201d: exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets","volume":"10","author":"Kang","year":"2014","journal-title":"Mol Biosyst"},{"key":"10.1016\/j.apsb.2021.11.018_bib121","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1517\/17460441.2015.1083007","article-title":"Fragment-based approaches to anti-HIV drug discovery: state of the art and future opportunities","volume":"10","author":"Huang","year":"2015","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.apsb.2021.11.018_bib122","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.2174\/09298673113209990001","article-title":"Virtual screening strategies in\u00a0drug\u00a0discovery: a critical review","volume":"20","author":"Lavecchia","year":"2013","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.apsb.2021.11.018_bib123","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.pbiomolbio.2015.01.009","article-title":"Flexibility and small pockets at protein\u2012protein interfaces: new insights into druggability","volume":"119","author":"Jubb","year":"2015","journal-title":"Prog Biophys Mol Biol"},{"key":"10.1016\/j.apsb.2021.11.018_bib124","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1021\/jm500300r","article-title":"Optimization of small-molecule inhibitors of influenza virus polymerase: from thiophene-3-carboxamide to polyamido scaffolds","volume":"57","author":"Lepri","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.11.018_bib125","doi-asserted-by":"crossref","DOI":"10.1002\/0471141755.ph0904s44","article-title":"Overview of high-throughput screening","author":"Entzeroth","year":"2009","journal-title":"Curr Protoc Pharmacol"},{"key":"10.1016\/j.apsb.2021.11.018_bib126","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/0929867053363540","article-title":"Bioisosterism: a useful strategy for molecular\u00a0modification and drug design","volume":"12","author":"Lima","year":"2005","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.apsb.2021.11.018_bib127","doi-asserted-by":"crossref","first-page":"6007","DOI":"10.1128\/AAC.00781-15","article-title":"Novel ranking system for identifying efficacious anti-influenza virus PB2 inhibitors","volume":"59","author":"Tsai","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2021.11.018_bib128","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1021\/jm2013503","article-title":"Design, synthesis, and in\u00a0vitro biological evaluation of 1H-1,2,3-triazole-4-carboxamide derivatives as new anti-influenza A agents targeting virus nucleoprotein","volume":"55","author":"Cheng","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.11.018_bib129","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1016\/j.bmcl.2008.02.020","article-title":"Enhanced anti-influenza A virus activity of (\u2012)-epigallocatechin-3-O-gallate fatty acid monoester derivatives: effect of alkyl chain length","volume":"18","author":"Mori","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2021.11.018_bib130","doi-asserted-by":"crossref","first-page":"31500","DOI":"10.1038\/srep31500","article-title":"N-Acylhydrazone inhibitors of influenza virus PA endonuclease\u00a0with versatile metal binding modes","volume":"6","author":"Carcelli","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2021.11.018_bib131","doi-asserted-by":"crossref","first-page":"414","DOI":"10.4103\/ijp.ijp_998_20","article-title":"Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients","volume":"52","author":"Prakash","year":"2020","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.apsb.2021.11.018_bib132","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.cell.2021.02.013","article-title":"Antivirals with common targets against highly pathogenic viruses","volume":"184","author":"Lu","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2021.11.018_bib133","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1126\/science.abb7498","article-title":"Structure of the RNA-dependent RNA polymerase from COVID-19 virus","volume":"368","author":"Gao","year":"2020","journal-title":"Science"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383521004561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383521004561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:18:47Z","timestamp":1762604327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383521004561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":133,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S2211383521004561"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2021.11.018","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contemporary medicinal chemistry strategies for the discovery and optimization of influenza inhibitors targeting vRNP constituent proteins","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2021.11.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}